It seems that Teva is actively seeking partnerships for late-stage drugs.
Teva Pharmaceuticals is looking to build out its pipeline as its “pivot to growth” strategy begins to take shape, CEO Richard Francis said on the company’s earnings call.
The generics giant has been investing heavily in R&D, with an emphasis on Phase III programs in asthma and schizophrenia. When it comes to new deals, Francis is particularly interested in late-stage or early commercial assets. And he now has more firepower, thanks to a $500 million upfront payment from Teva’s recent anti-TL1A deal with Sanofi.
“We’re a very attractive company if somebody wants to partner a product, if they’re a small biotech or if they’re a big company that doesn’t have the ability to really launch it properly,” Francis told Endpoints News in an interview Wednesday. “Obviously the Sanofi deal helps.”